CN109260136A - 一种护眼霜及其制备方法 - Google Patents
一种护眼霜及其制备方法 Download PDFInfo
- Publication number
- CN109260136A CN109260136A CN201811442949.1A CN201811442949A CN109260136A CN 109260136 A CN109260136 A CN 109260136A CN 201811442949 A CN201811442949 A CN 201811442949A CN 109260136 A CN109260136 A CN 109260136A
- Authority
- CN
- China
- Prior art keywords
- eye
- vitamin
- eyeshield
- frost
- eye cream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006071 cream Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims abstract description 16
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 15
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 241001506047 Tremella Species 0.000 claims abstract description 15
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000017700 silymarin Nutrition 0.000 claims abstract description 15
- 229960004245 silymarin Drugs 0.000 claims abstract description 15
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 13
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 229930182817 methionine Natural products 0.000 claims abstract description 13
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940038879 chelated zinc Drugs 0.000 claims abstract description 12
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 11
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 10
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 10
- 239000011648 beta-carotene Substances 0.000 claims abstract description 10
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 10
- 229960002747 betacarotene Drugs 0.000 claims abstract description 10
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 10
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 10
- 239000000230 xanthan gum Substances 0.000 claims abstract description 8
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 8
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- 230000001804 emulsifying effect Effects 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 235000010443 alginic acid Nutrition 0.000 claims description 14
- 239000000783 alginic acid Substances 0.000 claims description 14
- 229960001126 alginic acid Drugs 0.000 claims description 14
- 229920000615 alginic acid Polymers 0.000 claims description 14
- 150000004781 alginic acids Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 11
- 241000218236 Cannabis Species 0.000 claims description 11
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 11
- 229930003448 Vitamin K Natural products 0.000 claims description 11
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 11
- 235000019155 vitamin A Nutrition 0.000 claims description 11
- 239000011719 vitamin A Substances 0.000 claims description 11
- 235000019168 vitamin K Nutrition 0.000 claims description 11
- 239000011712 vitamin K Substances 0.000 claims description 11
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 11
- 229940045997 vitamin a Drugs 0.000 claims description 11
- 229940046010 vitamin k Drugs 0.000 claims description 11
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 claims description 9
- 239000004909 Moisturizer Substances 0.000 claims description 9
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 230000001333 moisturizer Effects 0.000 claims description 9
- 229920002643 polyglutamic acid Polymers 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- -1 sorbitan fatty acid ester Chemical class 0.000 claims description 9
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 claims description 9
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 50
- 239000002994 raw material Substances 0.000 abstract description 16
- 210000001328 optic nerve Anatomy 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 4
- 230000036737 immune function Effects 0.000 abstract description 3
- 235000012680 lutein Nutrition 0.000 abstract description 3
- 229960005375 lutein Drugs 0.000 abstract description 3
- 239000001656 lutein Substances 0.000 abstract description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 abstract description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 abstract description 3
- 230000004089 microcirculation Effects 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 abstract description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 abstract description 3
- 238000001467 acupuncture Methods 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract description 2
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 230000000474 nursing effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 231100000344 non-irritating Toxicity 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000001914 calming effect Effects 0.000 abstract 1
- 239000010460 hemp oil Substances 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 26
- 230000004438 eyesight Effects 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 16
- 208000001491 myopia Diseases 0.000 description 11
- 210000005036 nerve Anatomy 0.000 description 10
- 239000003876 biosurfactant Substances 0.000 description 9
- 230000037111 immune power Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 230000004379 myopia Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 239000000661 sodium alginate Substances 0.000 description 6
- 235000010413 sodium alginate Nutrition 0.000 description 6
- 229940005550 sodium alginate Drugs 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- CYGIJEJDYJOUAN-UHFFFAOYSA-N Isosilychristin Natural products C1=C(O)C(OC)=CC(C2C3C=C(C4C(C3=O)(O)OCC42)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-UHFFFAOYSA-N 0.000 description 4
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 4
- 229950011318 cannabidiol Drugs 0.000 description 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 238000001223 reverse osmosis Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001886 ciliary effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- RIAZZJBPJQWPIS-UHFFFAOYSA-N Silychristin Natural products COc1cc(ccc1O)C2OC3C(C=C(C=C3O)C4Oc5cc(O)cc(O)c5C(=O)C4O)C2CO RIAZZJBPJQWPIS-UHFFFAOYSA-N 0.000 description 2
- MZBGBHVFCYCYLX-UHFFFAOYSA-N Silydianin Natural products COc1cc(ccc1O)C2C3COC4(O)C3C=C(C5Oc6cc(O)cc(O)c6C(=O)C5O)C2C4=O MZBGBHVFCYCYLX-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical group C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- BMLIIPOXVWESJG-LMBCONBSSA-N silychristin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@@H](C3=C(C(=CC(=C3)[C@@H]3[C@H](C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-LMBCONBSSA-N 0.000 description 2
- BMLIIPOXVWESJG-UHFFFAOYSA-N silychristin A Natural products C1=C(O)C(OC)=CC(C2C(C3=C(C(=CC(=C3)C3C(C(=O)C4=C(O)C=C(O)C=C4O3)O)O)O2)CO)=C1 BMLIIPOXVWESJG-UHFFFAOYSA-N 0.000 description 2
- CYGIJEJDYJOUAN-JSGXPVSSSA-N silydianin Chemical compound C1=C(O)C(OC)=CC([C@H]2[C@H]3C=C([C@@H]4[C@@](C3=O)(O)OC[C@@H]42)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 CYGIJEJDYJOUAN-JSGXPVSSSA-N 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 244000198134 Agave sisalana Species 0.000 description 1
- 235000011624 Agave sisalana Nutrition 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009185 Ciliary muscle spasm Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 229930013035 isoflavonoid derivative Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000004423 myopia development Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004436 pseudomyopia Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于护眼霜/膏技术领域,更具体地涉及一种为眼部周围血管和穴位提供易吸收利用的营养物质的护眼霜,采用黄原胶、蛋氨酸螯合锌、银耳提取物、珍珠粉、大麻油、水飞蓟素、壳寡糖、β‑胡萝卜素、葛根素、环糊精等作为护眼霜的原料,主要原料均来自纯天然,辅助制剂和添加剂也均是温和不刺激的,对人体眼部幼嫩肌肤及其温和,主要原料组分对眼部皮肤的护理为复合且长效的舒缓视神经、促进微循环,而非单纯传统眼霜或眼膏的瞬时滋养,在镇静和舒缓视神经之外,还有强化眼部免疫功能的有益组分,大大增强了眼部抵抗疲劳和环境威胁的能力,在眼部护理和增强方面,提供了叶黄素和Omega‑3之外的营养素选择。
Description
技术领域
本发明属于护眼霜/膏技术领域,更具体地涉及一种为眼部周围血管和穴位提供易吸收利用的营养物质的护眼霜。
背景技术
眼霜,作为广大女性常用的护肤类化妆产品之一,大致分为眼膜、眼胶、眼部啫喱、眼贴、眼霜等,从功能上分为滋润眼霜、紧实眼霜、抗老化眼霜、抗敏眼霜等等。虽然,许多品种的眼霜具有良好的保养和美容效果,但是对于眼部的持续护理、营养补充及强化视力功能方面,未发现科研成果及实际产品的应用推广案例。
在调节放松的状态下,平行光线经眼球屈光系统后聚焦在视网膜之前,称为近视。近视眼也称短视眼,因为近视眼只能看近不能看远。这种眼在休息时,从无限远处来的平行光经过眼的屈光系折光之后,在视网膜之前集合成焦点,在视网膜上则结成不清楚的像,远视力明显降低,但近视力尚正常。近视的内因有:遗传因素和发育因素;近视的外因:即环境因素,从事文字工作或其他近距离工作的人,近视眼比较多,青少年学生中近视眼也比较多,而且从小学五、六年级开始,其患病率明显上升。这种现象说明近视眼的发生和发展与近距离工作的关系非常密切。尤其是青少年的眼球,正处于生长发育阶段,调节能力很强,球壁的伸展性也比较大,阅读等近距离工作时的调节和集合作用,使内直肌对眼球施加一定的压力,眼内压也相应升高,随着作业的不断增加,调节和集合的频度和时间也逐渐增加,睫状肌和眼外肌经常处于高度紧张状态,调节作用的过度发挥可以造成睫状肌痉挛,从而引起一时性的视力减退。但经休息或使用睫状肌糜烂剂后,视力可能改善或完全恢复。因此,有人称这种近视为功能性近视或假性近视。
现有的一些治疗方案有,1、配戴眼镜;2、手术治疗:角膜手术,晶状体及人工晶状体手术,巩膜后部加固术;3、药物治;4、其他治疗:其他凡无害于眼而有一定理论依据的治疗方法,如雾视法、双眼合像法及合像增视仪、远眺法、睫状肌锻炼法等均可试用。
对于预防近视和矫正,出现了用于视力检测的视力筛选仪,视力筛选仪检测且适用于儿童和成人:1、自动,无损伤性;2、快速而有效;3、无需病人做出反应;4、适用于儿童;5、客观性;6、安全、准确的屈光信息。同时检测仪设计使筛选更容易1、简便易携;2、舒适精巧的设计;3、严密的保护箱;4、筛查范围广。
以上传统方法都未从视力与人体肝脏的经络联系方面入手,且多数时候需要依赖医疗机构和专业医护人员的治疗,为眼部患者增添了许多麻烦,开发一款简便、有效、日常的护眼用品非常有必要也有意义。
发明内容
为此,需要提供一种护眼霜,为眼部护理和营养加强以改善视力提供有效的日常生活用品。
为实现上述目的,发明人提供了一种护眼膏或者护眼霜,其包括下列重量份的组分:
保湿剂和表面活性剂是皮肤保养品或护肤品中常用的原料组分,但不同于传统的膏霜类产品,这两种原料组分在本技术方案中的用量并非主要的,而必须与原料配方中的水飞蓟素、黄原胶、大麻油和蛋氨酸螯合锌的量相协调,找到各自独立的最适用量。
黄原胶又称黄胶、汉生胶,是一种由黄单胞杆菌发酵产生的细胞外酸性杂多糖,黄原胶对不溶性固体和油滴具有良好的悬浮作用,黄原胶溶胶分子能形成超结合带状的螺旋共聚体,构成脆弱的类似胶的网状结构,所以能够支持固体颗粒、液滴和气泡的形态,显示出很强的乳化稳定作用和高悬浮能力,而其在本技术方案中的作用除了协同表面活性剂的优秀增稠和乳化作用,更为关键的是其对热、酶解、盐和酸碱的稳定性很强,有利于增强护眼霜产品的稳定性。
蛋氨酸螯合锌是由蛋氨酸与无机硫酸锌、氧化锌通过化学合成反应以1:1或2:1的摩尔比在一定的温度、压力、反应时间等作用下生产而成的一种有机锌类物质,其比无机锌更易于被皮肤吸收,充分融合了蛋氨酸对眼部皮肤的营养作用和锌元素对维生素A正常代谢的双重功效。
银耳提取物含有海藻糖、多缩戊糖、甘露糖醇等肝糖,营养价值很高,具有扶正强壮的作用,是一种高级滋养补品。现代医学研究证实,银耳的药理有效成分是银耳多糖:主要有酸性多糖、中性杂多糖、酸性低聚糖等组成,银耳多糖有明显的抗氧化作用,并具有增强人体细胞免疫和体液免疫的作用,因此银耳提取物对眼周皮肤具有保湿滋养以及增强眼部免疫力的功效。
珍珠粉除了大众所熟知的美白护肤功效之外,本技术方案中主要利用其中的牛磺酸成分,牛磺酸本身具有良好的镇静安神功效,可用来调节中枢神经系统,它还可以增强心肌的收缩力,防治心脏功能衰竭,治疗心血管病,发明人惊喜地发现,该成分对舒缓眼周神经、促进眼部肌肉修复同样具有较好效果。
大麻油,其有效成分为大麻二酚(CBD),是大麻中的主要化学成分之一,提取自雌性大麻植株,与大麻中另一个化学成分四氢大麻酚(THC)不同的是,大麻二酚(CBD)为非致毒活性成分,研究实验表明其能有效活化血管,促进血液循环。
水飞蓟素,外文名称为Silymarin,是天然的黄酮木脂素类化合物,系从菊科植物水飞蓟的干燥果实中提取而得到的天然活性物质,其主要成分为水飞蓟宾(silybin)、异水飞蓟宾(isosilybim)、水飞蓟宁(silydianin)和水飞蓟亭(silychristin)。清除活性氧,直接清除活性氧,对抗脂质过氧化,维持细胞膜的流动性,水飞蓟素具有很强的抗氧化功能,其保护肝脏细胞免受自由基破坏的效力远胜于维生素E,此外,水飞蓟素能促进蛋白质的合成,加快制造新的肝脏细胞,或令已受损的肝脏细胞自行修复。因此被称为“天然的保肝药”。
壳寡糖又叫壳聚寡糖、低聚壳聚糖,是将壳聚糖经特殊工艺降解得到的一种聚合度在2~20之间寡糖产品,分子量≤3200Da,是水溶性较好、功能作用大、生物活性高的低分子量产品。它具有壳聚糖所没有的较高溶解度,全溶于水,容易被生物体吸收利用等诸多独特的功能,其作用为壳聚糖的14倍,采用壳寡糖旨在提高本技术方案产品的以下性能:保湿性、活化机体细胞,阻止皮肤粗糙和老化。
维生素A(VitaminA,简称VA)是人体必需的一类微量营养素,包括两种活性亚型:VA1视黄醇和VA2视黄醛,以VA1为主,本发明主要应用维生素A在维持视力、免疫功能方面的生理功能。
维生素E为公知的抗氧化剂,是一种脂溶性维生素,因此,它在空气中无法长期稳定存在,具有很强的还原性,但其用量也并非越多越维生素好,因其存在对其他的脂溶性维生素有阻碍作用或是拮抗作用,通过试验发现,维生素E合适的用量为0.9-1.5份。
维生素K又叫凝血维生素,是维生素的一种,天然的维生素K已经发现有两种:一种是维生素K1,另一种是维生素K2,维生素K在动物肝中广泛存在,是合成四种凝血蛋白必不可少的因子,在本技术方案中,维生素K的存在可以很巧妙地平衡维生素E生理功能最佳发挥。
β-胡萝卜素是类胡萝卜素之一,它是自然界中最普遍存在也是最稳定的天然色素,分子结构相当于2个分子的维生素A,进入机体后,在肝脏及小肠粘膜内经过酶的作用,其中50%变成维生素A,有补肝明目的作用。与叶黄素类似,它也是一种重要的抗氧化剂,本发明采用β-胡萝卜素的原因,一方面考虑到其清肝明目的作用,另一方面也考虑到其可刺激皮肤的新陈代谢,增进血液循环。
葛根素亦称葛根黄素,是从中药葛根中分离的具有扩冠作用的异黄酮类衍生物。本技术方案利用葛根素作为主要的原料组分,好处在于,它能够与多种原料组分协同作用,对视神经具有营养镇静功效,而且其所含的皂苷类化合物具有降低血管阻力、改善微循环的作用。
环糊精(Cyclodextrin,简称CD)是直链淀粉在由芽孢杆菌产生的环糊精葡萄糖基转移酶作用下生成的一系列环状低聚糖的总称,通常含有6~12个D-吡喃葡萄糖单元。采用其作为原料的好处在于,环糊精的外缘亲水而内腔疏水,因而环糊精包合物具有亲水性,能够将脂溶性且暴露于环境中易被氧化的物质包合在其中,并且不改变被包合物的物理和化学物质,具有极强的稳定性,能够持续缓释其所包合的有效功能组分,结合一些按摩和弱电极刺激可以有效释放包合的化合物成分,起到稳定产品质量,又能保障质量的作用。
优选地,所述护眼霜包括以下重量份的组分:
优选地,所述保湿剂是聚谷氨酸和海藻酸的混合物。
目前的保养和美容膏霜类产品多数采用市售的海藻酸钠为保湿剂,但钠离子属于不必要被皮肤摄入的成分,而且若皮肤摄入了多余的钠离子,会因为渗透压改变对皮肤产生不好的影响,因此,本发明中采用反渗透膜技术对原料进行前处理,将海藻酸钠中的钠离子加以去除,用得到的海藻酸作为辅助保湿剂,与天然微生物发酵的产物聚谷氨酸配合使用,可以避免皮肤过敏反应并增强产品的稳定性,并且海藻酸可以和具有抗菌生物活性的壳寡糖成分形成弱酸碱中和,更好的稳定和分散霜剂或者膏剂产品,本发明在长期的研发和实验过程中所分析得到的最佳配伍,同时能很好或者稳定其他成分的活性,而不会影响产品变质或者出水。
优选地,所述表面活性剂是由生物表面活性剂surfactin、失水山梨醇脂肪酸酯Span或吐温80中的一种或几种组成。
膏霜的加工过程加入表面活性剂能够保持产品的稳定,本发明所要采用的表面活性剂除了需要具备优良的乳化能力和分散力,还需要兼备生物安全性、温和无毒及良好的增稠性能,而生物表面活性剂surfactin是由枯草芽孢杆菌产生的迄今为止发现的活性最强的脂肽类生物表面活性剂之一,因此,由生物表面活性剂surfactin、失水山梨醇脂肪酸酯Span或吐温80中的一种或两种以上的组合组成表面活性剂能够使上述原料组份形成很好的油包水结构,并且以较好的浓稠膏/霜体状态呈现。
发明人还提供了一种护眼霜的制备方法,其包括以下步骤:
备料:按配方量量取保湿剂、表面活性剂、黄原胶、蛋氨酸螯合锌、银耳提取物、珍珠粉、大麻油、水飞蓟素、壳寡糖、维生素A、维生素E、维生素K、β-胡萝卜素、葛根素、环糊精及去离子水,备用;
预处理:将维生素A和维生素K用环糊精进行包合,得到包合物;混合搅拌:将保湿剂、蛋氨酸螯合锌、银耳提取物、珍珠粉、水飞蓟素、壳寡糖、β-胡萝卜素和葛根素混合搅拌,并梯度加热至25℃~50℃得到预混合物;
混合乳化:将大麻油、维生素E、表面活性剂及所述包合物加入所述预混合物中混合乳化,冷却出料得到成品;
静置杀菌:将所述成品进行静置杀菌,得到霜体;
灌装:将上述霜体按照规格含量灌装入包装瓶,即为护眼霜产品。
进一步地,所述混合搅拌步骤的时间为15-60min。
由于原料组分在水中或者油中的溶解性质不同,要做成霜或者膏的产品,关键在于水相和油乳的混合搅拌工艺上,因此,在梯度加热的基础上,应适当设置搅拌时间,使水油混合程度达到要求。
进一步地,所述混合乳化时的工艺条件为可调均质功率15kw,均质转速为2500~3500rpm,均质时间为10-60min。
乳化均质是食品或化工行业生产中常用的一项技术,是使悬浮液(或乳化液)体系中的分散物微粒化、均匀化的处理过程,这种处理同时起降低分散物尺度和提高分散物分布均匀性的作用,均质乳化过程就是依靠搅拌装置的机械作用所产生的剪切力,将分散相切割成微粒而分散在连续相中,形成霜状均相物。剪切力的大小直接影响着分散情况的好坏,油性成分与水溶性成分要达到高速均浆,对均质乳化的转速要求较高。
区别于现有技术,上述技术方案采用保湿剂、表面活性剂、黄原胶、蛋氨酸螯合锌、银耳提取物、珍珠粉、大麻油、水飞蓟素、壳寡糖、维生素A、维生素E、维生素K、β-胡萝卜素、葛根素、环糊精及去离子水作为护眼霜的原料,具有以下优点:
(1)主要原料均来自纯天然,辅助制剂和添加剂也均是温和不刺激的,对人体眼部幼嫩肌肤极其温和;
(2)主要原料组分对眼部皮肤的护理为复合且长效的舒缓视神经、促进微循环,而非单纯传统眼霜或眼膏的瞬时滋养;
(3)在镇静和舒缓视神经之外,还有强化眼部免疫功能的有益组分,大大增强了眼部抵抗疲劳和环境威胁的能力;
(4)在眼部护理和增强方面,提供了叶黄素和Omega-3之外的营养素选择;
(5)选用易得的海藻酸钠然后经过加工处理获得海藻酸,既作为保湿剂,又作为产品稳定剂成分。
具体实施方式
为详细说明技术方案的技术内容、构造特征、所实现目的及效果,以下结合具体实施例详予说明。
实施例中所涉及的药物或原料均为能够通过常规途径获取得到的,其中海藻酸是由采购自市场的海藻酸钠经反渗透膜技术处理得到,视力检测采用常规的视力表并结合检测眼睛的屈光度的视力检测仪进行。
实施例1
制备第一种能增强眼部免疫力和舒缓神经的护眼霜
将海藻酸钠经反渗透膜技术处理,得到分析纯的海藻酸;量取聚谷氨酸和海藻酸的混合物150g(聚谷氨酸和海藻酸的重量比为1:1)、失水山梨醇脂肪酸酯(Span)100g、黄原胶120g、蛋氨酸螯合锌11g、银耳提取物40g、珍珠粉135g、大麻油18g、水飞蓟素45g、壳寡糖130g、维生素A70g、维生素E90g、维生素K15g、β-胡萝卜素140g、葛根素150g、环糊精200g及去离子水2000g;
预处理:将维生素A和维生素K用环糊精进行包合反应,得到包合物;混合搅拌:将聚谷氨酸和海藻酸的混合物、蛋氨酸螯合锌、银耳提取物、珍珠粉、水飞蓟素、壳寡糖、β-胡萝卜素和葛根素混合搅拌,并边搅拌边以5℃的梯度加热至35℃得到预混合物,搅拌时间为40min;
混合乳化:将大麻油、维生素E、失水山梨醇脂肪酸酯(Span)及所述包合物加入所述预混合物中,在可调均质功率为15kw,均质转速为3500rpm条件下,均质乳化时间为30min,冷却出料得到成品;静置杀菌:将所述成品进行静置紫外杀菌,得到霜体;
灌装:将上述霜体按照规格含量灌装入洁净干燥的包装瓶,即为护眼霜产品。
比较例1
制备第二种能增强眼部免疫力和舒缓神经的护眼霜
除了将实施例1中混合搅拌步骤边搅拌边以5℃的梯度加热至50℃得到预混合物,搅拌时间为40min,其他条件均与实施例1一致,制备得到了第二种能增强眼部免疫力和舒缓神经的护眼霜。
比较例2
除了将实施例1中混合乳化时的工艺条件调整为均质乳化功率为15kw,均质转速为2500rpm,均质时间为20min,其他条件均与实施例1一致,制备得到了第三种能增强眼部免疫力和舒缓神经的护眼霜。
实验例1
试验方法:以4名年龄为30周岁、从事相似职业(以电脑文案工作为主)、初始视力相同(均为1.2)的女性作为测试对象。将受试者分为4组,前3组受试者相同地在眼周相同部位、每天晚上睡前分别擦拭实施例1、比较例1、比较例2方法制得的护眼霜,按摩5分钟,进行眼周皮肤擦拭按摩试验,将最后1组受试者设为空白组不做任何处理,为期6个月,每个月对受试者进行跟踪测试,试验结果如表1所示:
表1 30周岁女性用后视力结果数据
护眼霜 | 第一个月 | 第二个月 | 第三个月 | 第四个月 | 第五个月 | 第六个月 |
实施例1 | 1.2 | 1.2 | 1.2 | 1.5 | 1.5 | 1.5 |
比较例1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.5 | 1.5 |
比较例2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.5 |
空白组 | 1.2 | 1.2 | 1.2 | 1.0 | 1.0 | 1.0 |
实验例2
试验方法:以4名年龄为15周岁、初始视力相同(均为1.0)的男生作为测试对象,将受试者分为4组,前三组相同地在眼周相同部位、每天晚上睡前分别擦拭实施例1、比较例1、比较例2方法制得的护眼霜,按摩5分钟,进行眼周皮肤擦拭按摩试验,将最后1组受试者设为空白组不做任何处理,为期6个月,每个月对受试者进行跟踪测试,试验结果如表2所示:
表2 15周岁男生用后视力结果数据
护眼霜 | 第一个月 | 第二个月 | 第三个月 | 第四个月 | 第五个月 | 第六个月 |
实施例1 | 1.0 | 1.0 | 1.2 | 1.2 | 1.2 | 1.2 |
比较例1 | 1.0 | 1.0 | 1.0 | 1.0 | 1.2 | 1.2 |
比较例2 | 1.0 | 1.0 | 1.0 | 1.0 | 1.2 | 1.2 |
空白组 | 1.0 | 1.0 | 1.0 | 0.8 | 0.8 | 0.8 |
实施例2
制备第四种能增强眼部免疫力和舒缓神经的护眼霜
将海藻酸钠经反渗透膜技术处理,得到分析纯的海藻酸;量取聚谷氨酸和海藻酸的混合物120g(聚谷氨酸和海藻酸的重量比为1:1)、生物表面活性剂surfactin100g、黄原胶160g、蛋氨酸螯合锌10g、银耳提取物60g、珍珠粉130g、大麻油10g、水飞蓟素30g、壳寡糖130g、维生素A80g、维生素E120g、维生素K20g、β-胡萝卜素120g、葛根素120g、环糊精250g及去离子水3420g;
预处理:将维生素A和维生素K用环糊精进行包合反应,得到包合物;混合搅拌:将聚谷氨酸和海藻酸的混合物、蛋氨酸螯合锌、银耳提取物、珍珠粉、水飞蓟素、壳寡糖、β-胡萝卜素和葛根素混合搅拌,并边搅拌边以5℃的梯度加热至50℃得到预混合物,搅拌时间为60min;
混合乳化:将大麻油、维生素E、生物表面活性剂surfactin及所述包合物加入所述预混合物中,在可调均质功率为15kw,均质转速为3500rpm条件下,均质乳化时间为60min,冷却出料得到成品;静置杀菌:将所述成品进行静置紫外杀菌,得到霜体;
灌装:将上述霜体按照规格含量灌装入洁净干燥的包装瓶,即为护眼霜产品。
比较例3
制备第五种能增强眼部免疫力和舒缓神经的护眼霜
除了将实施例2中生物表面活性剂surfactin改为等量的吐温80之外,其他条件均与实施例2一致,制备得到了第五种能增强眼部免疫力和舒缓神经的护眼霜。
比较例4
制备第六种能增强眼部免疫力和舒缓神经的护眼霜
除了将实施例2中生物表面活性剂surfactin改为等量的吐温80、失水山梨醇脂肪酸酯(Span)和生物表面活性剂surfactin(以重量比1:1:1添加)之外,其他条件均与实施例2一致,制备得到了第五种能增强眼部免疫力和舒缓神经的护眼霜。
实验例3
试验方法:以4名年龄为12周岁、生活习惯基本相似(看书、写作业等)、初始视力相同(均为1.5)的女生作为测试对象,将受试者分为4组,前三组相同地在眼周相同部位、每天晚上睡前分别擦拭实施例2、比较例3、比较例4方法制得的护眼霜,按摩5分钟,进行眼周皮肤擦拭按摩试验,将最后1组受试者设为空白组不做任何处理,为期6个月,每个月对受试者进行跟踪测试,试验结果如表3所示:
表3 12周岁女生用后视力结果数据
护眼霜 | 第一个月 | 第二个月 | 第三个月 | 第四个月 | 第五个月 | 第六个月 |
实施例2 | 1.5 | 1.5 | 1.5 | 1.5 | 2.0 | 2.0 |
比较例3 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 2.0 |
比较例4 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
空白组 | 1.5 | 1.5 | 1.5 | 1.5 | 1.2 | 1.2 |
实验例4
试验方法:以4名年龄为40周岁、生活习惯基本相似、初始视力相同(均为1.5)的女性作为测试对象,将受试者分为4组,前三组相同地在眼周相同部位、每天晚上睡前分别擦拭实施例2、比较例3、比较例4方法制得的护眼霜,按摩5分钟,进行眼周皮肤擦拭按摩试验,将最后1组受试者设为空白组不做任何处理,为期6个月,每个月对受试者进行跟踪测试,试验结果如表4所示:
表4 40周岁女性用后视力结果数据
护眼霜 | 第一个月 | 第二个月 | 第三个月 | 第四个月 | 第五个月 | 第六个月 |
实施例2 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 2.0 |
比较例3 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 2.0 |
比较例4 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
空白组 | 1.5 | 1.5 | 1.5 | 1.2 | 1.2 | 1.2 |
从上述四张表中的实验数据可知,同样年龄段、相同性别、职业和生活习惯的受试者在接受不同方法制备的护眼霜时,按照实施例1和实施例2方法制备出的护眼霜对受试者视力的保健作用更佳,改变了工艺条件的比较例方法制备出的护眼霜效果略差,而将三种不同方法制备出的护眼霜与不做任何处理的受试者进行对比,则按照本技术方案制得的护眼霜有着明显的视力保护和增强效果,空白组的受试者在不做任何视力保健和眼部营养加强的处理下,随着时间推移,用眼过度、蓝光危害等导致视力下降。
从上述实施例可以看出,对于不同的年龄、性别、从事不同职业的人群,擦拭本技术方案的护眼霜,均能起到舒缓眼部神经、增强眼部免疫力的功效,可以证明该产品对于各阶段人群的眼部保健都有积极作用。
该护眼霜/膏产品结合穴位按摩治疗进行复健,同时为了提高产品的吸收和发挥作用,可以结合微电极按摩器进行,能对眼部附近的血管进行作用,促进眼部血液循环,起到很好的辅助治疗效果。
需要说明的是,尽管在本文中已经对上述各实施例进行了描述,但并非因此限制本发明的专利保护范围。因此,基于本发明的创新理念,对本文所述实施例进行的变更和修改,或利用本发明说明书内容所作的等效结构或等效流程变换,直接或间接地将以上技术方案运用在其他相关的技术领域,均包括在本发明的专利保护范围之内。
Claims (7)
1.一种护眼霜,其特征在于,包括下列重量份的组分:
2.根据权利要求1所述的护眼霜,其特征在于,所述护眼霜包括以下重量份的组分:
3.根据权利要求1或2所述的护眼霜,其特征在于,所述保湿剂是聚谷氨酸和海藻酸的混合物。
4.根据权利要求1或2所述的护眼霜,其特征在于,所述表面活性剂是由生物表面活性剂surfactin、失水山梨醇脂肪酸酯Span或吐温80中的一种或几种组成。
5.一种护眼霜的制备方法,其特征在于,包括以下步骤:
备料:按配方量量取保湿剂、表面活性剂、黄原胶、蛋氨酸螯合锌、银耳提取物、珍珠粉、大麻油、水飞蓟素、壳寡糖、维生素A、维生素E、维生素K、β-胡萝卜素、葛根素、环糊精及去离子水,备用;
预处理:将维生素A和维生素K用环糊精进行包合,得到包合物;混合搅拌:将保湿剂、蛋氨酸螯合锌、银耳提取物、珍珠粉、水飞蓟素、壳寡糖、β-胡萝卜素和葛根素混合搅拌,并梯度加热至25℃~50℃得到预混合物;
混合乳化:将大麻油、维生素E、表面活性剂及所述包合物加入所述预混合物中混合乳化,冷却出料得到成品;
静置杀菌:将所述成品进行静置杀菌,得到霜体;
灌装:将上述霜体按照规格含量灌装入包装瓶,即为护眼霜产品。
6.根据权利要求5所述的制备方法,其特征在于,所述混合搅拌步骤的时间为15-60min。
7.根据权利要求5所述的制备方法,其特征在于,所述混合乳化时的工艺条件为可调均质功率15kw,均质转速为2500~3500rpm,均质时间为10-60min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811442949.1A CN109260136A (zh) | 2018-11-29 | 2018-11-29 | 一种护眼霜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811442949.1A CN109260136A (zh) | 2018-11-29 | 2018-11-29 | 一种护眼霜及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109260136A true CN109260136A (zh) | 2019-01-25 |
Family
ID=65186868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811442949.1A Withdrawn CN109260136A (zh) | 2018-11-29 | 2018-11-29 | 一种护眼霜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109260136A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111097036A (zh) * | 2019-05-05 | 2020-05-05 | 刘祝成 | 眼部护理组合物、产品及其使用方法 |
WO2021018934A1 (en) * | 2019-07-29 | 2021-02-04 | Echo Pharmaceuticals B.V. | Treatment of sebaceous gland disorders |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101041846A (zh) * | 2007-01-29 | 2007-09-26 | 中国科学院等离子体物理研究所 | 新型脂肽类生物表面活性剂surfactin的制备方法及用途 |
CN107648148A (zh) * | 2016-07-25 | 2018-02-02 | 周丽 | 含鳄梨油的8小时保湿眼霜及其制备方法 |
CN108392458A (zh) * | 2018-04-27 | 2018-08-14 | 陈艳琳 | 一种芦荟眼霜的制备方法 |
CN109010169A (zh) * | 2018-08-28 | 2018-12-18 | 安徽科技学院 | 一种滁菊眼霜的制备方法 |
-
2018
- 2018-11-29 CN CN201811442949.1A patent/CN109260136A/zh not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101041846A (zh) * | 2007-01-29 | 2007-09-26 | 中国科学院等离子体物理研究所 | 新型脂肽类生物表面活性剂surfactin的制备方法及用途 |
CN107648148A (zh) * | 2016-07-25 | 2018-02-02 | 周丽 | 含鳄梨油的8小时保湿眼霜及其制备方法 |
CN108392458A (zh) * | 2018-04-27 | 2018-08-14 | 陈艳琳 | 一种芦荟眼霜的制备方法 |
CN109010169A (zh) * | 2018-08-28 | 2018-12-18 | 安徽科技学院 | 一种滁菊眼霜的制备方法 |
Non-Patent Citations (1)
Title |
---|
杨建峰: "《你不知道的美容养颜小偏方》", 30 April 2014, 江西科学技术出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111097036A (zh) * | 2019-05-05 | 2020-05-05 | 刘祝成 | 眼部护理组合物、产品及其使用方法 |
WO2021018934A1 (en) * | 2019-07-29 | 2021-02-04 | Echo Pharmaceuticals B.V. | Treatment of sebaceous gland disorders |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109091675B (zh) | 一种复方低浓度阿托品类药物滴眼液及其制备方法 | |
CN106333885A (zh) | 一种植物提取物及眼部精华液 | |
BRPI0711970A2 (pt) | composições e métodos de fucoidano | |
CN101505773A (zh) | 用于治疗眼病的药物 | |
CN102225087A (zh) | 一种强效护眼的叶黄素复方制剂 | |
CN107412258A (zh) | 一种具有缓解视疲劳功能的保健眼贴 | |
CN104147081A (zh) | 改善视力的蓝莓叶黄素软胶囊及制作方法 | |
CN107837288A (zh) | 一种缓解视疲劳的复方花青素叶黄素酯软胶囊 | |
CN103860625A (zh) | 越橘提取物眼用制剂及其制备方法和用途 | |
CN104824675A (zh) | 视力改善叶黄素胶囊 | |
CN104824510A (zh) | 具有视力保护作用的保健食品 | |
CN109260136A (zh) | 一种护眼霜及其制备方法 | |
CN104257727A (zh) | 缓解视疲劳软胶囊及加工方法 | |
CN108904633A (zh) | 一种改善视力的眼膏及其制备方法 | |
CN108125996A (zh) | 一种用于视疲劳、干眼的眼用制剂 | |
CN109288738A (zh) | 一种护眼组合物及其眼贴膜和制备方法 | |
CN113826894A (zh) | 一种缓解视疲劳胶囊及其制备方法 | |
CN105520137A (zh) | 一种具有缓解视疲劳和保护视力功能的保健食品 | |
CN102488266B (zh) | 叶黄素木糖醇营养饮品及其制备方法 | |
CN104958364A (zh) | 一种缓解视疲劳的越橘叶黄素制剂生产方法 | |
DE69823546T2 (de) | Verfahren zur beschleunigung der verdauung eines proteins und modifiziertes proteinprodukt | |
CN101785854B (zh) | 叶黄素多维营养保健药物组合物、其制备方法及应用 | |
CN1973873A (zh) | 眼保健食品胶囊 | |
CN101129698B (zh) | 一种含有黄姜提取物的滴眼液及其制备方法 | |
CN109481323A (zh) | 一种芦荟原汁保湿油及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190125 |